Healthcare provider profile · identity verified

Philbert Chow, MD

Family Practice · NEW YORK, NY · NPI 1235421157

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	388	118
Amlodipine Besylate	Amlodipine Besylate	291	98
Metformin Hcl	Metformin Hcl	284	76
Meloxicam	Meloxicam	237	77
Omeprazole	Omeprazole	216	72
Losartan Potassium	Losartan Potassium	168	51
Metoprolol Succinate	Metoprolol Succinate	164	53
Diclofenac Sodium	Diclofenac Sodium	161	53
Hydrochlorothiazide	Hydrochlorothiazide	155	50
Lisinopril	Lisinopril	151	51
Gabapentin	Gabapentin	150	56
Januvia	Sitagliptin Phosphate	148	32
Albuterol Sulfate Hfa	Albuterol Sulfate	146	48
Meclizine Hcl	Meclizine Hcl	141	46
Montelukast Sodium	Montelukast Sodium	129	43
Fluticasone Propionate	Fluticasone Propionate	124	50
Levothyroxine Sodium	Levothyroxine Sodium	119	35
Vascepa	Icosapent Ethyl	96	23
Vitamin D2	Ergocalciferol (Vitamin D2)	90	28
Simvastatin	Simvastatin	89	32
Rosuvastatin Calcium	Rosuvastatin Calcium	87	24
Azithromycin	Azithromycin	84	37
Ibuprofen	Ibuprofen	81	34
Ammonium Lactate	Ammonium Lactate	78	21
Alcohol Prep Pads	Alcohol Antiseptic Pads	74	24
Trazodone Hcl	Trazodone Hcl	72	24
Single Use Swab	Alcohol Antiseptic Pads	71	21
Furosemide	Furosemide	66	26
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	63	17
Jardiance	Empagliflozin	62	14
Buspirone Hcl	Buspirone Hcl	61	18
Famotidine	Famotidine	58	23
Enalapril Maleate	Enalapril Maleate	57	21
Ciprofloxacin Hcl	Ciprofloxacin Hcl	56	28
Tamsulosin Hcl	Tamsulosin Hcl	54	16
Glipizide Er	Glipizide	51	13
Quetiapine Fumarate	Quetiapine Fumarate	51	15
Eliquis	Apixaban	49	15
Glipizide	Glipizide	49	15
Donepezil Hcl	Donepezil Hcl	48	18
Alendronate Sodium	Alendronate Sodium	46	15
Pantoprazole Sodium	Pantoprazole Sodium	45	18
Linzess	Linaclotide	44	11
Ezetimibe	Ezetimibe	43	17
Memantine Hcl	Memantine Hcl	42	15
Silver Sulfadiazine	Silver Sulfadiazine	42	19
Triamcinolone Acetonide	Triamcinolone Acetonide	41	13
Janumet	Sitagliptin Phos/Metformin Hcl	40	suppressed
Kerendia	Finerenone	39	suppressed
Carvedilol	Carvedilol	38	16
Farxiga	Dapagliflozin Propanediol	38	12
Metoprolol Tartrate	Metoprolol Tartrate	38	15
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	38	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	37	13
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	36	suppressed
Pravastatin Sodium	Pravastatin Sodium	36	suppressed
Naproxen	Naproxen	34	12
Atenolol	Atenolol	33	suppressed
Ondansetron Hcl	Ondansetron Hcl	32	suppressed
Glimepiride	Glimepiride	29	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	29	suppressed
Mirtazapine	Mirtazapine	29	13
Ozempic	Semaglutide	29	suppressed
Valsartan	Valsartan	29	11
Mometasone Furoate	Mometasone Furoate	28	suppressed
Hydrocortisone	Hydrocortisone	27	12
Janumet Xr	Sitagliptin Phos/Metformin Hcl	27	suppressed
Nifedipine Er	Nifedipine	26	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	25	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	25	suppressed
Xarelto	Rivaroxaban	25	suppressed
Nystatin	Nystatin	24	11
Clopidogrel	Clopidogrel Bisulfate	23	13
Escitalopram Oxalate	Escitalopram Oxalate	23	suppressed
Hydralazine Hcl	Hydralazine Hcl	23	suppressed
Prednisone	Prednisone	23	16
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	22	13
Clotrimazole	Clotrimazole	21	suppressed
Loperamide	Loperamide Hcl	20	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	20	suppressed
Ventolin Hfa	Albuterol Sulfate	20	suppressed
Alcohol Swabs	Alcohol Antiseptic Pads	19	suppressed
Memantine Hcl Er	Memantine Hcl	19	suppressed
Sertraline Hcl	Sertraline Hcl	19	suppressed
Entresto	Sacubitril/Valsartan	18	suppressed
Ibu	Ibuprofen	18	suppressed
Novolog Flexpen	Insulin Aspart	18	suppressed
Procto-Med Hc	Hydrocortisone	18	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	18	suppressed
Valacyclovir	Valacyclovir Hcl	18	suppressed
Tolterodine Tartrate	Tolterodine Tartrate	16	suppressed
Tradjenta	Linagliptin	15	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	14	suppressed
Folic Acid	Folic Acid	14	suppressed
Gemfibrozil	Gemfibrozil	14	suppressed
Latanoprost	Latanoprost	14	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	13	suppressed
Repaglinide	Repaglinide	13	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	12	suppressed
Baclofen	Baclofen	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	12	suppressed
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Fluconazole	Fluconazole	12	suppressed
Lokelma	Sodium Zirconium Cyclosilicate	12	suppressed
Nabumetone	Nabumetone	12	suppressed
Rybelsus	Semaglutide	12	suppressed
Tresiba Flextouch U-100	Insulin Degludec	12	suppressed
Azelastine Hcl	Azelastine Hcl	11	suppressed
Celecoxib	Celecoxib	11	suppressed
Estradiol (Once Weekly)	Estradiol	11	suppressed
Finasteride	Finasteride	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error